ReviewDrugs2024
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease.
Review in Drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Perfluorohexyloctane eye drops in treating dry eye disease associated with meibomian gland dysfunction: a post hoc analysis by baseline severity.International ophthalmology · 2026Trial
- Bridging the gap: A new perspective on lid wiper epitheliopathy and meibomian gland inversion.Eye (London, England) · 2026Review
- Redefining Dry Eye Disease Management: Emerging Pharmacologic and Device-Based Therapies in the Era of Precision Care: A Narrative Review.Ophthalmology and therapy · 2026Review
- Pharmacological, Natural and Emerging Therapies for Meibomian Gland Dysfunction: A Review.Drugs · 2026Review
- An Overview of Rheumatoid Arthritis-Associated Dry Eye Disease, Scleritis, and Peripheral Ulcerative Keratitis.Journal of clinical medicine · 2026Review
- T-LysYal for Managing Dry Eye Disease, the Advent of Supramolecular Aggregates in Ophthalmology: A Narrative Review.Journal of clinical medicine · 2026Review
- Electroacupuncture Ameliorates Scopolamine-Induced Dry Eye Disease in Mice by Restoring Lacrimal Gland Lipid Homeostasis and Reducing IL-1β/IL-18 Expression.Journal of immunology research · 2026Article
- Disproportionality analyses of acoltremon: a real-world safety assessment based on the the FDA adverse event reporting system database.Frontiers in medicine · 2026Article
- Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study.Ophthalmology and therapy · 2025Article
- Investigating the Effect of Reducing the Signs and Symptoms of Lid Wiper Epitheliopathy in Patients With Dry Eye Disease With Perfluorohexyloctane.Current therapeutic research, clinical and experimental · 2025Article
- Corneal Mucin-Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Meibomian gland lipid alterations and ocular surface sequela in Awat2 knockout murine model of meibomian gland dysfunction and evaporative dry eye disease.The ocular surface · 2024Article
- Navigating dry eye relief: Meibo's approach to controlling tear evaporation.Annals of medicine and surgery (2012) · 2024Article
- Topical Application of a Novel Harderian-Derived Nonpolar Lipid Prolongs Tear Film Breakup Time in Normal Beagle Dogs.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and TherapeuticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perfluorohexyloctane ophthalmic solution (Miebo
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.